Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Narayan, Gopeshwar ^a   Goparaju, Chandra ^a   Arias Pulido, Hugo ^b,e   Kaufmann, Andreas M ^c   Schneider, Achim ^c   Dürst, Matthias ^d   Mansukhani, Mahesh ^a   Pothuri, Bhavana ^a   Murty, Vundavalli V ^a  

^a Columbia University ^*  (United States)

^b Instituto Nacional de Cancerología   (Colombia)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; HISTONE DEACETYLASE; ROUNDABOUT RECEPTOR; SLIT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; DATA ANALYSIS; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRECANCER; PROMOTER REGION; RECEPTOR BINDING; SOMATIC CELL; UTERINE CERVIX CANCER;

DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; RECEPTORS, IMMUNOLOGIC; UTERINE CERVICAL NEOPLASMS;

EID: 33745493625     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-16     Document Type: Article

References (31)

1. Hogg R, Friedlander M: Role of systemic chemotherapy in metastatic cervical cancer. Expert Rev Anticancer Ther 2003, 3:234-240.
2. Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003, 3:55-63.
3. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
4. Guan H, Zu G, Xie Y, Tang H, Johnson M, Xu X, Kevil C, Xiong WC, Elmets C, Rao Y, Wu JY, Xu H: Neuronal repellent Slit2 inhibits dendritic cell migration and the development of immune responses. J Immunol 2003, 171:6519-6526.
5. Park KW, Morrison CM, Sorensen LK, Jones CA, Rao Y, Chien CB, Wu JY, Urness LD, Li DY. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol 2003, 261:251-267.
6. Wong K, Park HT, Wu JY, Rao Y: Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Curr Opin Genet Dev 2002, 12:583-591.
7. Dallol A, Forgacs E, Martinez A, Sekido Y, Walker R, Kishida T, Rabbitts P, Maher ER, Minna JD, Latif F: Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTTI (ROBO1) in human cancers. Oncogene 2002, 21:3020-3028.
8. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, Latif F: SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 2002, 62:5874-5880.
9. Dallol A, Krex D, Hesson L, Eng C, Maher ER, Latif F: Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene 2003, 22:4611-4616.
10. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F, Kishida T, Grundy R, Yao M, Latif F, Maher ER: Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 2003, 22:6794-6801.
11. Astuti D, Da Silva NF, Dallol A, Gentle D, Martinsson T, Kogner P, Grundy R, Kishida T, Yao M, Latif F, Maher ER: SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma. Br J Cancer 2004, 90:515-521.
12. Mitra AB, Murty VV, Li RG, Pratap M, Luthra UK, Chaganti RS: Allelotype analysis of cervical carcinoma. Cancer Res 1994, 54:4481-4487.
13. Pulido HA, Fakruddin MJ, Chatterjee A, Esplin ED, Beleno N, Martinez G, Posso H, Evans GA, Murty VV: Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res 2000, 60:6677-6682.
14. Xian J, Aitchison A, Bobrow L, Corbett G, Pannell R, Rabbitts T, Rabbitts P: Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter. Cancer Res 2004, 64:6432-6437.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
16. Dickinson RE, Dallol A, Bieche I, Krex D, Morton D, Maher ER, Latif F: Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer 2004, 91:2071-2078.
17. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993.
18. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP: DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl. Cancer Inst 2002, 94:755-761.
19. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, Ro JY: Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am Pathol 2002, 160:787-794.
20. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
21. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, Kitano S, Hirohashi S: Increased DNA methyltransferase I (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004, 164:689-699.
22. Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, Baylin SB, Schuebel KE: De novo CpG island methylation in human cancer cells. Cancer Res 2006, 66:682-692.
23. Prasad A, Fernandis AZ, Rao Y, Ganju RK- Slit protein-mediated inhibition of CXCR4-induced chernotactic and chemoinvasive signaling pathways in breast cancer cells. J Biol Chem 2004, 279:9115-9124.
24. Syrjanen KJ: Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol 1996, 65:45-53.
25. Marillat V, Cases O, Nguyen-Ba-Charvet KT, Tessier-Lavigne M, Sotelo C, Chedotal A: Spatiotemporal expression patterns of slit and robo genes in the rat brain. J Comp Neurol 2002, 442:130-155.
26. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167.
27. Soprano DR, Qin P, Soprano KJ: Retinoic acid receptors and cancers. Annu Rev Nutr 2004, 24:201-221.
28. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine. Mol Pharmacol 2004, 65:18-27.
29. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV: Frequent Promoter Methylation of CDH1 DAPK, RARB, and H1C1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome. Mol Cancer 2003, 2:24.
30. Narayan G, Pulido HA, Koul S, Lu XY, Harris CP, Yeh YA, Vargas H, Posso H, Terry MB, Gissmann L, Schneider A, Mansukhani M, Rao PH, Murty VV: Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003, 22:3489-3499.
31. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Durst M, Pothuri B, Murty VV: Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004, 64:2994-2997.